Mometasone furoate/formoterol in the treatment of persistent asthma

被引：0
作者：
Berger, William E. [1 ]
机构：
[1] Allergy & Asthma Associates, Mission Viejo, CA 92961 USA
来源：
EXPERT REVIEW OF RESPIRATORY MEDICINE | 2011年 / 5卷 / 06期
关键词：
anti-inflammatory; asthma; asthma deterioration; beta-agonist; bronchodilator; control; corticosteroid; exacerbation; inhaler; quality of life; 200/10; MU-G; DOUBLE-BLIND; END-POINTS; FORMOTEROL; SAFETY; GLUCOCORTICOIDS; DURATION; INHALERS; EFFICACY; FUROATE;
D O I：
10.1586/ERS.11.71
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Mometasone furoate and formoterol fumarate dihydrate (MF/F) administered via metered-dose inhaler with a dose counter is a new fixed-dose combination of an inhaled corticosteroid and a long-acting beta 2-agonist indicated for daily maintenance therapy in patients aged >= 12 years with persistent asthma. Randomized, controlled trials have suggested that MF/F reduces asthma deteriorations while improving lung function and other measures of asthma control, including quality-of-life. Clinical safety studies lasting up to 1 year have found that MF/F has a low incidence of local and systemic side effects.
引用
收藏
页码：739 / 746
页数：8
相关论文
共 42 条
12345